This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Twelve hospitals across India will be part of the network which will support the trial in India
Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Subscribe To Our Newsletter & Stay Updated
